for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Addex Therapeutics Ltd

ADXN.S

Latest Trade

1.66CHF

Change

-0.01(-0.30%)

Volume

8,553

Today's Range

1.62

 - 

1.67

52 Week Range

1.43

 - 

2.52

As of on the SIX Swiss Exchange ∙ Minimum 15 minute delay

Latest Developments

Addex Therapeutics H1 Net Profit Swings To Loss Of CHF 7.5 Mln

Sept 30 (Reuters) - ADDEX THERAPEUTICS LTD <ADXN.S>::DIPRAGLURANT PIVOTAL PHASE 2B/3 CLINICAL TRIAL ON TRACK TO DOSE FIRST PATIENT IN Q1 2020 AND READOUT TOPLINE RESULTS IN Q3 2021.INCOME OF CHF1.2 MILLION IN FIRST-HALF 2019.NET LOSS OF CHF7.5 MILLION IN FIRST-HALF 2019, COMPARED TO A NET INCOME OF CHF2.4 MILLION FOR FIRST-HALF 2018.H1 TOTAL OPERATING LOSS CHF 7.5 MILLION VERSUS PROFIT CHF 2.5 MILLION YEAR AGO.

Addex Therapeutics Increases Issued Share Capital

May 20 (Reuters) - ADDEX THERAPEUTICS LTD <ADXN.S>::INCREASES ISSUED SHARE CAPITAL AND CREATES TREASURY SHARES.HAS INCREASED ITS CAPITAL FROM 28,564,031 TO 32,848,635 THROUGH THE ISSUE OF 4,284,604 NEW REGISTERED SHARES.TRANSACTION WAS EXECUTED TO PROVIDE ADDITIONAL TREASURY SHARES THAT CAN BE USED TO RAISE FUNDS IN EFFICIENT MANNER.

Addex Therapeutics FY Net Loss At CHF 1.6 Mln

April 30 (Reuters) - ADDEX THERAPEUTICS LTD <ADXN.S>::NET LOSS FOR 2018 WAS CHF1.6 MILLION COMPARED TO CHF3.2 MILLION FOR 2017.

Addex Therapeutics FY Oper Income Down At CHF 6.8 Mln

March 8 (Reuters) - Addex Therapeutics Ltd <ADXN.S>::FY NET CASH FROM OPERATING ACTIVITIES OF CHF1.9 MILLION (2017: CHF1.2 MILLION).FY OPERATING INCOME OF CHF6.8 MILLION (2017: CHF4.9 MILLION).FY OPERATING COSTS OF CHF8.1 MILLION (2017: CHF3.8 MILLION).FY NET LOSS OF CHF1.6 MILLION (2017: CHF3.2 MILLION).

Addex Therapeutics H1 Net Income At CHF 2.4 Million

Sept 28 (Reuters) - Addex Therapeutics Ltd <ADXN.S>::COMPLETED FIRST HALF 2018 WITH CHF43.6 MILLION IN CASH AND CASH EQUIVALENTS.H1 REPORTED NET INCOME OF CHF2.4 MILLION.INCOME IN FIRST HALF 2018 WAS CHF5.4 MILLION, COMPARED TO CHF0.2 MILLION IN FIRST HALF 2017.

Addex: Selective mGlu2 PAM ADX71149 Shows Promise In Treating Severe Panic Disorders And PTSD

Sept 4 (Reuters) - Addex Therapeutics Ltd <ADXN.S>::ADDEX’S SELECTIVE MGLU2 PAM ADX71149 SHOWS PROMISE IN TREATING SEVERE PANIC DISORDERS AND PTSD.

Addex Therapeutics FY Net Loss At CHF 3.3 Million

April 30 (Reuters) - Addex Therapeutics Ltd <ADXN.S>::NET LOSS FOR 2017 FINANCIAL YEAR WAS CHF3.3 MILLION COMPARED TO CHF3.1 MILLION FOR 2016.CASH AND CASH EQUIVALENTS INCREASED BY 83% TO CHF2.6 MILLION AT 31 DECEMBER 2017.

Addex Secures Investor Commitment For CHF 40 Million Capital Increase

March 5 (Reuters) - ADDEX <ADXN.S>::SECURES INVESTOR COMMITMENT FOR CHF40 MILLION CAPITAL INCREASE.

Addex Therapeutics Launches CHF 40 Mln Capital Increase

Feb 15 (Reuters) - ADDEX THERAPEUTICS LTD <ADXN.S>::LAUNCHES CHF40 MILLION CAPITAL INCREASE WITH COMMITMENT FROM SPECIALIST US HEALTHCARE INVESTORS.TO INCREASE ITS SHARE CAPITAL BY ISSUING UP TO 12,779,553 NEW SHARES AT A PRICE OF CHF 3.13‍​.

Addex Therapeutics: Cash Position Of CHF 6.5 Mln As Of Jan. 31, 2018

Feb 5 (Reuters) - Addex Therapeutics Ltd <ADXN.S>::CASH POSITION OF CHF6.5 MILLION AS OF 31 JANUARY 2018.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up